Purchase this article with an account.
Masanori Miyazaki, Mitsuru Arima, Ryo Asato, Tatsuro Ishibashi; Changes And Correlations In Aqueous Levels Of Triamcinolone Acetonide And Vascular Endothelial Growth Factor After Intravitreal Triamcinolone Acetonide In Vitrectomized Human Eyes With Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1252.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the concentration-time profile of triamcinolone acetonide(TA) and vascular endothelial growth factor(VEGF) after a single, 8mg, intravitreal injection of TA(IVTA) in human vitrectomized eyes with central retinal vein occlusion(CRVO).
3 vitrectomized eyes with persistent macular edema(ME) secondary to CRVO were participated. 100 microliters of aqueous were sampled 1 week, 1, 3, and 6 months after IVTA 8mg. All procedures adhered to the tenets of the Declaration of Helsinki, and informed consent was obtained from all participants. Aqueous levels of TA and VEGF were measured by enzyme-linked immunosorbent assay. Best-corrected visual acuity(BCVA) and foveal thickness(FT) by OCT were also measured.
The concentrations of TA were 0.0, 1028.1, 385.3, 8.4, and 0.3ng/ml at before IVTA, 1 week, 1, 3, and 6 months after IVTA. Those of VEGF were 177.6, 107.6, 111.2, 168.4, and 120.8 pg/ml, which showed transient decrease by IVTA. BCVA and FT were improved until 3 months, however, worsen again at 6 months.
The concentration of TA could be detected slightly until 6months even in vitrectomized human eyes. TA-dependent constant and transient decrease of VEGF may possibly contribute to the improvement of ME with CRVO.
This PDF is available to Subscribers Only